Sarcopenia: How Muscle Loss Became a Diagnosable Condition

Sarcopenia became a diagnosable condition the moment a committee agreed on numbers. In 2019, the European Working Group on Sarcopenia in Older People published a revised consensus, widely called EWGSOP2, that reorganized the definition around muscle strength rather than muscle mass and attached explicit cut-points to each measurement (Age and Ageing, 2019). Under that framework, a grip strength below 27 kilograms in men or 16 kilograms in women signals probable sarcopenia, and the slow weakening that older adults had long described in words became a set of thresholds a clinician can check. What follows is a look at how that construct was assembled, because sarcopenia is a clear example of something built from measurements rather than discovered under a microscope.

From "you are getting weaker" to a code in the chart

For most of medical history, age-related muscle loss was a description, not a diagnosis. That changed in stages. In October 2016, sarcopenia received its own code in the United States clinical modification of the International Classification of Diseases, M62.84, formally recognizing it as an independent reportable condition (J Cachexia Sarcopenia Muscle, 2016). A billing code is a bureaucratic artifact, yet it carries weight: it lets clinicians distinguish age-related muscle decline from the muscle wasting of cancer, inflammatory myopathy, or neuromuscular disease, and it gives researchers and drug developers a defined target to enroll and study. A condition becomes real, in the operational sense, when the system can name it and count it.

The 2010 starting point: mass first

The original 2010 EWGSOP consensus put muscle quantity at the center. It asked for both low muscle mass and low muscle function, and it derived its thresholds statistically, setting cut-points roughly two standard deviations below the mean of a young reference population (Age and Ageing, 2010). That approach borrowed directly from how osteoporosis was defined by bone density, and it treated dwindling muscle mass as the core lesion. It also introduced conceptual stages, from presarcopenia through sarcopenia to severe sarcopenia.

The trouble was that muscle mass turned out to be a mediocre predictor of the outcomes people actually care about, such as falls, disability, and mortality. Strength tracked those outcomes better than size did, and mass measured by different machines gave different answers. So the working group revisited its own construct.

What EWGSOP2 changed: strength as the gateway

The 2019 revision made a deliberate reversal. It placed low muscle strength ahead of low muscle mass as the principal determinant, on the reasoning that strength is the parameter most tightly linked to poor outcomes and the easiest to measure reliably in practice (PMC6322506). Strength became the entry gate.

The operational cut-points are specific. Grip strength below 27 kilograms in men and 16 kilograms in women counts as low, or alternatively a chair stand test taking longer than 15 seconds to complete five rises. Meet either, and a person has probable sarcopenia. Confirmation then requires evidence of reduced muscle quantity or quality, with appendicular skeletal muscle mass below 20 kilograms in men and 15 kilograms in women, or below 7.0 kilograms per square meter of height in men and 5.5 in women, measured by DXA, bioimpedance, CT, or MRI. Severity is graded by physical performance: a gait speed of 0.8 meters per second or slower, a Short Physical Performance Battery score of 8 or below, or a Timed Up and Go of 20 seconds or more.

Assembling the construct: Find, Assess, Confirm, Severity

EWGSOP2 packaged these numbers into a four-step pathway abbreviated F-A-C-S. Find uses a brief symptom questionnaire, SARC-F, to flag people at risk. Assess measures strength to establish probable sarcopenia. Confirm documents low muscle mass to make the diagnosis. Severity uses performance testing to stage it. Probable sarcopenia is low strength alone, confirmed sarcopenia is low strength plus low mass, and severe sarcopenia is all three impaired.

Read the algorithm closely and you can see the anatomy of a diagnosis. Each stage is a threshold, each threshold is a line drawn across a continuous variable, and the diagnosis is the pattern of which lines a person has crossed. Nothing about grip strength changes at 26.9 versus 27.1 kilograms; the number is a convention chosen to separate populations, not a biological cliff.

Why the cut-point is a choice, not a fact

This is the part evidence literacy demands. A cut-point encodes a trade-off between catching true cases and mislabeling healthy people, and moving it shifts how many people carry the diagnosis. Different expert groups have chosen different numbers, and prevalence estimates swing accordingly depending on which definition and which cut-points a study applies. That variability is not a flaw to be embarrassed about; it is what happens whenever a spectrum is converted into a category.

The stakes are concrete in drug development, a domain I have worked in directly. A diagnostic definition is simultaneously the enrollment gate that decides who enters a trial and the scaffold for the endpoint that decides whether a therapy worked. If the construct is unstable or measures the wrong thing, muscle-targeted programs can enroll heterogeneous populations and struggle to show benefit on outcomes that matter. Much of the motivation behind a consensus definition and a formal disease code was to give trials a stable, agreed target so that a treatment effect could be measured consistently. The lesson generalizes: the quality of a diagnosis sets a ceiling on the quality of the evidence built on top of it.

What this means for a reader

If a clinician measures your grip or times you rising from a chair, they are running a validated screen, not passing a verdict on your future. Cut-points are population tools, and a person sitting near a threshold is not meaningfully different from one just across it. The practical value of naming sarcopenia is that it directs attention to strength and function as things worth measuring and, where appropriate, addressing, rather than dismissing weakness as inevitable. This article is educational and is not medical advice.

Understanding sarcopenia this way, as a construct assembled from thresholds, is a useful habit to carry into any modern diagnosis. The numbers are real and evidence-based, and they are also chosen, which is exactly why knowing where they come from repays the effort.